A Phase 2/3 Double-Blind, Randomized, Placebo-Controlled Adaptive Design Trial to Evaluate the Efficacy and Safety of Intravenous ACU193 in Early Alzheimer's Disease
Latest Information Update: 31 Mar 2025
At a glance
- Drugs Sabirnetug (Primary)
- Indications Alzheimer's disease
- Focus Registrational; Therapeutic Use
- Acronyms ALTITUDE-AD
- Sponsors Acumen Pharmaceuticals
Most Recent Events
- 27 Mar 2025 According to an Acumen Pharmaceuticals media release, Company expects topline results in late 2026.
- 12 Mar 2025 According to an Acumen Pharmaceuticals media release, data from this will be presented at the International Conference on Alzheimer's and Parkinsons Diseases and Related Neurological Disorders (AD/PD) in Vienna, Austria from April 1-5, 2025, and the American Academy of Neurology (AAN) Annual Meeting. on April 1, 2025, 2:30-2:45 p.m. CES, in Austria Center Vienna, Hall A San Diego, Calif. and April 7, 2025, 2:24 p.m. PT in San Diego Convention Center, 25C.
- 19 Dec 2024 Status changed from recruiting to active, no longer recruiting.